EUVIMEDEUVIMED entdecken
Evaluationsstudie

Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp

Volkan Beylergil, Laura Collins, Lawrence H Schwartz, Thomas Eche, Binsheng Zhao, Stephane Champiat, Richard Carvajal, Shaad E Abedin, Laurent Dercle

European Journal of Cancer · 2025

DOI: 10.1016/j.ejca.2025.115386 ↗

Kurz gefasst

Evaluationsstudie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Volkan Beylergil und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Columbia University Medical Center/NewYork-Presbyterian Hospital, 161 Fort Washington Avenue, New York, NY 10032, USA. Hauptthemen laut MEDLINE: Melanoma, Recombinant Fusion Proteins, Uveal Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: RSNA Research and Educational Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaRecombinant Fusion ProteinsUveal NeoplasmsAdultAgedFemaleHumansMaleMiddle AgedBiomarkers, TumorCirculating Tumor DNADisease ProgressionMagnetic Resonance ImagingRadiomicsTomography, X-Ray ComputedUveal MelanomaClinical Trials, Phase II as TopicClinical Trials, Phase I as TopicSecondary Data Analysis

Stichwörter der Autor:innen

Circulating tumor DNA (ctDNA)Metastatic uveal melanomaRadiomics analysisTebentafuspTumor heterogeneity

Substanzen

Biomarkers, TumorCirculating Tumor DNARecombinant Fusion Proteins

Autor:innen und Institutionen

  • Department of Radiology, Columbia University Medical Center/NewYork-Presbyterian Hospital, 161 Fort Washington Avenue, New York, NY 10032, USA.
  • Immunocore, 92 Park Drive, Milton Park, Abingdon, Oxfordshire OX14 4RY, United Kingdom.
  • Gustave Roussy, Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), 114 Rue Edouard Vaillant, Villejuif 94805, France.
  • Immunocore, 9801 Washingtonian Boulevard, Suite 800, Gaithersburg, MD 20878, USA.
  • Department of Radiology, Columbia University Medical Center/NewYork-Presbyterian Hospital, 161 Fort Washington Avenue, New York, NY 10032, USA. Electronic address: ld2752@cumc.columbia.edu.

Förderung

  • RSNA Research and Educational Foundation

Zitieren

APA

Beylergil, V., Collins, L., Schwartz, L. H., Eche, T., Zhao, B., Champiat, S., Carvajal, R., Abedin, S. E., & Dercle, L. (2025). Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115386

Vancouver

Beylergil V, Collins L, Schwartz LH, Eche T, Zhao B, Champiat S, et al. Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115386

BibTeX
@article{Beylergil2025,
  author = {Beylergil, Volkan and Collins, Laura and Schwartz, Lawrence H and Eche, Thomas and Zhao, Binsheng and Champiat, Stephane and Carvajal, Richard and Abedin, Shaad E and Dercle, Laurent},
  title = {Radiomic markers associated with clinical benefit in patients with radiographic progression of advanced uveal melanoma on tebentafusp},
  journal = {European Journal of Cancer},
  year = {2025},
  doi = {10.1016/j.ejca.2025.115386}
}
Kostenlos starten →